Research and Markets has announced the addition of the "Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Pipeline Insights, 2017" report to their offering.
Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors.
This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors.
This report also assesses the Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
Key Topics Covered:
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Overview
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Disease Associated
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Pipeline Therapeutics
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Therapeutics under Development by Companies
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Filed and Phase III Products
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Phase II Products
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Phase I and IND Filed Products
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Discovery and Pre-Clinical Stage Products
- Drug Candidate Profiles
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Therapeutics Assessment
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Discontinued Products
- Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors
- Appendix
For more information about this report visit http://www.researchandmarkets.com/research/67chzx/type_1
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005757/en/